摘要
目的观察抗趋化因子配体(CCL)20抗体对小鼠变应性鼻炎的抑制作用。方法选用BALB/c小鼠30只,随机分为变应性鼻炎(AR)组、CCL20单克隆抗体组和对照组,每组各10只。AR组及CCL20单克隆抗体组以卵清蛋白加入氢氧化铝佐剂行腹腔注射建立AR动物模型,CCL20单克隆抗体组再予CCL20单克隆抗体0.5mg/kg腹腔注射,对照组则以0.9%氯化钠溶液腹腔注射。模型建立后第2天处死小鼠并取其鼻腔黏膜及胸腺组织,对各组动物进行AR症状评分,应用酶联免疫吸附法(ELISA)、逆转录聚合酶链反应(RT-PCR)分别测定鼻腔黏膜中CCL20的蛋白含量及基因表达情况,并应用流式细胞仪测定胸腺中CD4+及CD25+T细胞的比例。结果①AR症状评分:AR组、CCL20单克隆抗体组的症状评分分别为(6.0±0.8)、(4.1±1.1)分,两组间的差异有统计学意义(P<0.05);且均显著高于对照组的(0.7±0.5)分。②小鼠鼻腔黏膜中CCL20mRNA相对表达量:AR组、CCL20单克隆抗体组CCL20mRNA相对表达量分别为13.49±0.65、13.21±0.53,均显著高于对照组的12.61±0.25(P值均<0.05);AR组与CCL20单克隆抗体组间CCL20mRNA相对表达量的差异无统计学意义(P>0.05)。③胸腺中CD4+及CD4+CD25+T细胞计数:AR组、CCL20单克隆抗体组的胸腺CD4+T细胞比例分别为(92.3±1.2)%、(91.0±0.7)%,均显著高于对照组的(86.6±2.9)%(P值均<0.05);但AR组与CCL20单克隆抗体组间的差异无统计学意义(P>0.05)。AR组、CCL20单克隆抗体组胸腺CD4+CD25+T细胞比例分别为(1.43±0.17)%、(2.38±0.43)%,均显著低于对照组的(4.05±0.68)%(P值均<0.05);AR组与CCL20单克隆抗体组的差异有统计学意义(P<0.05)。结论 CCL20单克隆抗体可阻断CCL20/趋化因子受体6通路,能有效地抑制小鼠AR的症状。
Objective To determine the therapeutic effect of anti-chemokine ligand 20（CCL 20）monoclonal antibody on allergic rhinitis（AR）in mice.Methods A total of 30 healthy BALB/c mice were randomized into normal control group,AR model group and CCL20 monoclonal antibody treatment group.In the latter 2 groups AR was sensitized by intraperitoneal injecting 0.1% ovalbumin with Al（OH）3（as supplement）in abdomen（once per 2 d for total 7 times）and then challenged by 2% ovalbumin（once per day for 7 times）.After the induction of AR,mice of CCL20 monoclonal antibody treatment group received an intraperitoneal injection of CL20 monoclonal antibody at 0.5 mg/kg for 5 d,and those of AR model group received an injection of normal saline.All mice were sacrificed after AR evalustion.The expressions of CCL20 mRNA and protein in nasal mucosa,and CD4＋T cells in thymus were determined by reverse transcription polymerase chain reaction（RT-PCR）,enzyme-linked immuno sorbent assay（ELISA）,and flow cytometry,and the results were compared among the 3 groups.Results Symptom score of AR group was significantly higher than that of control group（6.0±0.8 vs.0.7±0.5,P0.05）.Compared with the AR group,the score of CCL20 antibody group was significantly lower（4.1±1.1,P0.05）,though significantly higher than that of control（P0.05）.In both AR model group and CCL20 antibody group,the expressions of CCL20 mRNA in nasal mucosa were up-regulated when compared with that of control（13.49±0.65 and 13.21±0.53 vs.12.61±0.25,P0.05）.There was no significant difference in CCL20 mRNA levels between AR model group and CCL20 antibody group（P0.05）.Compared with the control group,the proportion of CD4＋ T cells in thymuses of AR model group and treatment group were increased（[92.3±1.2]% and [91.0±0.7]% vs.[86.6±2.9]%,P0.05）,but there was no significant difference between the former 2 groups（P0.05）.The proportion of CD4＋CD25＋ T cells were（1.43±0.17）% and（2.38±0.43）% in thymuses of AR model gro
出处
《上海医学》
CAS
CSCD
北大核心
2011年第3期214-217,共4页
Shanghai Medical Journal
